Preferred Label : TRAC Locus Integrated Anti-CD19 19(T2)28z1xx CAR-T Cells;
NCIt synonyms : TRAC Locus Integrated CD19-targeted CAR T-cells; 19(T2)28z1xx TRAC T Cells; 19(T2)28z1xx TRAC-CAR T Cells;
NCIt definition : A preparation of T-lymphocytes that have been genetically modified to express a chimeric
antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, linked to
the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of the
TCR/CD3 complex (CD3-zeta) (CD28zeta; CD28z), and inserted into the T-cell receptor
alpha constant (TRAC) locus, with potential immunostimulating and antineoplastic activities.
Upon administration, the TRAC locus integrated anti-CD19 19(T2)28z1xx CAR-T cells
specifically recognize and bind to CD19-expressing tumor cells, resulting in specific
T-cell-mediated tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen
overexpressed in B-cell lineage malignancies. CD28 and CD3zeta provide co-stimulatory
activity and may enhance the cytotoxic effect and anti-tumor activity of the CAR T-cells.
The 19(T2)28z1xx CAR includes a 1928zeta mutant, 1xx, which contains one instead of
all three immunoreceptor tyrosine-based activation motifs (iTAMs). This may help prevent
counterproductive T-cell differentiation and exhaustion. Integrating the anti-CD19
CAR to the TRAC locus may enhance both T-cell potency and the re-expression of the
CAR following exposure to antigen.;
NCI Metathesaurus CUI : CL1907092;
Origin ID : C200264;
concept_is_in_subset
- has_target
